Reata Pharmaceuticals, Inc. to Report First Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on May 10, 2022
May 02 2022 - 4:31PM
Business Wire
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the
“Company,” “our,” “us,” or “we”), a clinical-stage
biopharmaceutical company, today announced that it will report
financial results for the first quarter ended March 31, 2022, and
provide an update on the Company’s business operations and clinical
development programs on May 10, 2022, before the U.S. financial
markets open.
Conference Call Information
Reata’s management will host a conference call on May 10, 2022,
at 8:30 am ET. The conference call will be accessible by dialing
(844) 200-6205 (toll-free domestic) or (929) 526-1599
(international) using access code 488160. The webcast link is
https://services.choruscall.com/mediaframe/webcast.html?webcastid=MTgDXzgf.
First quarter 2022 financial results to be discussed during the
call will be included in an earnings press release that will be
available on the company’s website shortly before the call at
https://www.reatapharma.com/investors/ and will be available for 12
months after the call. The audio recording and webcast of the
conference call will be accessible for at least 90 days after the
event at https://www.reatapharma.com/investors/.
About Reata
Reata is a clinical-stage biopharmaceutical company that
develops novel therapeutics for patients with serious or
life-threatening diseases by targeting molecular pathways involved
in the regulation of cellular metabolism and inflammation. Reata’s
two most advanced clinical candidates, omaveloxolone and
bardoxolone methyl, target the important transcription factor Nrf2
that promotes the resolution of inflammation by restoring
mitochondrial function, reducing oxidative stress, and inhibiting
pro-inflammatory signaling. Omaveloxolone and bardoxolone methyl
are investigational drugs, and their safety and efficacy have not
been established by any agency.
Forward-Looking Statements
This press release includes certain disclosures that contain
“forward-looking statements,” including, without limitation,
statements regarding the success, cost and timing of our product
development activities and clinical trials, our plans to research,
develop, and commercialize our product candidates, our plans to
submit regulatory filings, and our ability to obtain and retain
regulatory approval of our product candidates. You can identify
forward-looking statements because they contain words such as
“believes,” “will,” “may,” “aims,” “plans,” “model,” and “expects.”
Forward-looking statements are based on Reata’s current
expectations and assumptions. Because forward-looking statements
relate to the future, they are subject to inherent uncertainties,
risks, and changes in circumstances that may differ materially from
those contemplated by the forward-looking statements, which are
neither statements of historical fact nor guarantees or assurances
of future performance. Important factors that could cause actual
results to differ materially from those in the forward-looking
statements include, but are not limited to, (i) the timing, costs,
conduct, and outcome of our clinical trials and future preclinical
studies and clinical trials, including the timing of the initiation
and availability of data from such trials; (ii) the timing and
likelihood of regulatory filings and approvals for our product
candidates; (iii) whether regulatory authorities determine that
additional trials or data are necessary in order to obtain
approval; (iv) the potential market size and the size of the
patient populations for our product candidates, if approved for
commercial use, and the market opportunities for our product
candidates; and (v) other factors set forth in Reata’s filings with
the U.S. Securities and Exchange Commission, including its Annual
Report on Form 10-K for the fiscal year ended December 31, 2021,
under the caption “Risk Factors.” The forward-looking statements
speak only as of the date made and, other than as required by law,
we undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220502005701/en/
Reata Pharmaceuticals, Inc. (972) 865-2219
https://www.reatapharma.com/
Investor Relations & Media Relations: John Hunter
ir@reatapharma.com Wendy Segal media@reatapharma.com
https://www.reatapharma.com/contact-us/
Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From Sep 2023 to Sep 2024